Drugs / HB0036
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05417321 | Aug 2022 → Aug 2025 overdue | non-small cell lung carcinoma | Shanghai Huaota Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0036 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05417321 ↗ |
| Route | Intravenous | “HB0036 via intravenous infusion” NCT05417321 ↗ |